{"id":"injectable-subcutaneous-buprenorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, producing analgesia and euphoria at lower doses while exhibiting a ceiling effect on respiratory depression at higher doses. The subcutaneous injectable formulation provides sustained drug delivery for opioid use disorder treatment and pain management. Its high receptor binding affinity and long half-life make it suitable for maintenance therapy with reduced abuse potential compared to full mu-opioid agonists.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and suppress opioid withdrawal symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:07.607Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT07176351","phase":"PHASE4","title":"Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT04408313","phase":"PHASE2, PHASE3","title":"Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2020-10-28","conditions":"Opioid-use Disorder","enrollment":240},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT04060654","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-10-21","conditions":"Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate","enrollment":17},{"nctId":"NCT06880718","phase":"PHASE4","title":"Injectable Buprenorphine in Prison: a Preference Trial","status":"NOT_YET_RECRUITING","sponsor":"Lifespan","startDate":"2025-06","conditions":"Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder","enrollment":60},{"nctId":"NCT05704543","phase":"PHASE4","title":"Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2023-03-01","conditions":"Opioid Use Disorder","enrollment":132},{"nctId":"NCT04815590","phase":"","title":"Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose","status":"UNKNOWN","sponsor":"BC Centre on Substance Use","startDate":"2022-10-17","conditions":"Opioid-Use Disorder, Opioid Overdose","enrollment":40},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT04122755","phase":"PHASE1","title":"Single Ascending Dose Study of ALA-1000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2019-09-16","conditions":"Opioid-use Disorder","enrollment":59},{"nctId":"NCT02946073","phase":"PHASE3","title":"Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2016-09","conditions":"Chronic Lower Back Pain, Chronic Pain","enrollment":1053},{"nctId":"NCT03752528","phase":"","title":"Evaluation of Long-term Buprenorphine Plasma Exposure","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-02-19","conditions":"Opioid-use Disorder","enrollment":53},{"nctId":"NCT02672111","phase":"PHASE3","title":"Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-11","conditions":"Opioid Use Disorder","enrollment":228},{"nctId":"NCT02710526","phase":"PHASE2","title":"Phase II Pharmacokinetics Study of CAM2038","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-02","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":66},{"nctId":"NCT03809143","phase":"PHASE3","title":"Community Studies of Long Acting Buprenorphine (CoLAB)","status":"UNKNOWN","sponsor":"The University of New South Wales","startDate":"2019-05-22","conditions":"Opioid Dependence","enrollment":100},{"nctId":"NCT02611752","phase":"PHASE2","title":"A Multiple Dose Opioid Challenge Study","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-10","conditions":"Moderate or Severe Opioid Use Disorder","enrollment":47},{"nctId":"NCT02651584","phase":"PHASE3","title":"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-12","conditions":"Opioid Use Disorders","enrollment":428},{"nctId":"NCT02896296","phase":"PHASE3","title":"Open-Label Treatment Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-08-17","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":208},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT01738503","phase":"PHASE2","title":"Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-10","conditions":"Opioid Related Disorder","enrollment":124},{"nctId":"NCT02357901","phase":"PHASE3","title":"Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-01-28","conditions":"Opioid Dependence, Opioid Related Disorders","enrollment":665},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Injectable subcutaneous buprenorphine","genericName":"Injectable subcutaneous buprenorphine","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and suppress opioid withdrawal symptoms. Used for Opioid use disorder maintenance treatment, Moderate to severe pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}